**Core tip:** Gastric cancer develops even after successful *Helicobacter pylori* (*H. pylori*) eradication therapy. With the prevalence of eradication therapy, occurrence rates of gastric cancer detected after eradication are increasing and this is becoming an important clinical issue. We review the characteristics and predictors of primary gastric cancer after *H. pylori* eradication, and discuss the risk stratification of gastric cancer after eradication.

INTRODUCTION
============

Gastric cancer is one of the deadliest malignancies, with 1 million cases annually around the world. In the past, the standard curative treatment was surgical resection with lymph node dissection, as the disease was usually diagnosed in the advanced stages in symptomatic subjects. To improve the prognosis of gastric cancer, diagnostic instruments and techniques were developed in Japan, where the occurrence of, and mortality by, gastric cancer were extremely high. Surveillance by endoscopy is one of the methods that enable early diagnosis of gastric cancer. Not only through diagnosis but also by its therapeutic properties\[[@B1]\] endoscopy has changed the management, and improved the prognosis, of gastric cancer. The discovery of the gastric pathogen, *Helicobacter pylori* (*H. pylori*), which was recognized as a group 1 carcinogen\[[@B2]\], dramatically changed the image of gastric cancer from a cryptogenic devastating disease to an infectious, predictable and preventable one\[[@B3]\].

Warren and Marshall isolated *H. pylori* from gastric tissue with gastritis\[[@B4]\]. Initially the pathogenesis of this bacterium was examined in peptic ulcer patients. Developments of diagnostic procedures and antibiotics for *H. pylori* have improved the treatment of peptic ulcers\[[@B5]-[@B7]\]. Further research on this pathogen revealed its pathogenesis in relation to chronic gastritis and gastric cancer as well, with early studies demonstrating that *H. pylori* infection increased the risk for gastric cancer\[[@B8],[@B9]\]. Uemura et al\[[@B10]\] performed a cohort study of endoscopic surveillance of gastric cancer and found that all occurrences of gastric cancer in the cohort were in *H. pylori-*infected subjects. From these findings, *H. pylori* infection was incorporated into the previously proposed gastric carcinogenesis process known as Correa's cascade\[[@B11]-[@B13]\]. Specifically, *H. pylori* infection initiates sequential histological changes such as non-atrophic gastritis, atrophic gastritis\[[@B14]-[@B16]\], intestinal metaplasia\[[@B15]-[@B18]\], dysplasia, and intestinal-type gastric cancer\[[@B19]\]. In contrast, such a sequential model was not applicable to diffuse-type gastric cancer, though diffuse-type gastric cancer is also associated with *H. pylori* infection\[[@B20]-[@B22]\].

Based on these findings, other studies examined the effect of *H. pylori* eradication on preventing gastric cancer. Fukase et al\[[@B23]\] reported that metachronous development of gastric carcinoma was reduced by *H. pylori* eradication after endoscopic resection of early gastric cancer in an open-label multicenter randomized controlled trial. Wong et al\[[@B24]\] performed a prospective, randomized, placebo-controlled, population-based study to examine the association of primary gastric cancer and eradication therapy. The incidence of gastric cancer development was similar between the eradication-treatment group and placebo group in this study. However, in the subgroup without precancerous lesions, eradication significantly decreased the development of gastric cancer. Recent systematic reviews and meta-analysis showed reduction of primary and metachronous gastric cancer by *H. pylori* eradication\[[@B25]-[@B27]\]. Although the effect of *H. pylori* eradication on the prognosis is not determined yet, it is expected that *H. pylori* eradication and elimination within society will lead to less gastric cancer cases and a reduction of medical costs\[[@B28]\].

These reports on the effect of *H. pylori* eradication for gastric cancer also elucidated another important fact. That is, gastric cancer did develop in *H. pylori*-eradicated patients\[[@B29],[@B30]\], not only in gastric cancer-treated patients, who presumably possess the highest risk, but also in gastric-cancer naïve cases\[[@B24],[@B31]\]. Time from eradication to cancer occurrence varied from several months to more than 10 years\[[@B31],[@B32]\]. Therefore, identification of high-risk subjects, who would benefit from extensive surveillance, is an important clinical problem. Many earlier studies have investigated differences in gastric cancers that developed in *H. pylori-*infected and eradicated patients, to assist the early and accurate diagnosis in eradicated cases. Recent studies, which included a relatively large number of *H. pylori*-eradicated cohorts, enabled analysis of the risk factors of future gastric cancer development.

The purpose of this review article was to summarize the characteristics of gastric cancer that developed after *H. pylori-*eradication therapy, and also to identify the predictors of primary gastric cancer. Many previous studies have examined risk factors for metachronous gastric cancer development, in follow-up or cross-sectional studies of endoscopically removed gastric cancer cases\[[@B33]-[@B37]\]. Because these cohorts had already developed gastric cancer, they benefited from multiple, surveillance endoscopy as well as *H. pylori* eradication. There are many review articles on this specific topic\[[@B38]-[@B40]\]. However, these patients who once had gastric cancer are high-risk patients anyway, and close follow-up should be required. In contrast, a review article for the risk factors in gastric-cancer naïve cases after *H. pylori* eradication, which would be valuable for stratifying huge numbers of *H. pylori*-eradicated patients according to gastric cancer risk, has not been conducted thus far. The findings of this article will be useful for establishing a proper follow-up strategy for *H. pylori*-eradicated subjects.

ENDOSCOPIC AND HISTOLOGICAL CHARACTERISTICS OF GASTRIC CANCER AFTER *H.PYLORI* ERADICATION
==========================================================================================

Endoscopic features
-------------------

Many studies have examined the endoscopic findings of primary gastric cancer after *H. pylori* eradication. Most of these studies were derived from early gastric cancer cases who underwent endoscopic treatment and, therefore, potentially include selection bias.

**Depressed lesion:** One of the notable endoscopic features of gastric cancer after *H. pylori* eradication is its depressed appearance. Kamada et al. reported that among 20 gastric cancer cases discovered in *H. pylori-*eradicated patients, 90% (18 cases) were ulcer type\[[@B41]\]. In a recent and relatively large propensity score-matching study of endoscopic submucosal dissection cases, 81% (78 of 96) of early gastric cancers from *H. pylori-*eradicated patients were depressed type, a significantly higher proportion than the 53% (51 of 96) in *H. pylori-*positive cases\[[@B42]\]. Many other studies, including case series\[[@B43]\], or case control studies\[[@B44],[@B45]\] also indicated predominance of depressed or ulcer type (0-IIc) gastric cancer in *H. pylori-*eradicated cases (Table [1](#T1){ref-type="table"}).

###### 

Endoscopic and histological characteristics of gastric cancer after *Helicobacter pylori* eradication

  **Ref**.                    **Number of gastric cancer after eradication/during infection**   **Study design**                 **Case recruitment**         **Characteristics**
  --------------------------- ----------------------------------------------------------------- -------------------------------- ---------------------------- -------------------------------------------------------------------------------------------------
  Shichijo et al\[[@B31]\]    21/NA                                                             Case series                      Surveillance                 Intestinal type
  Maehata et al\[[@B42]\]     96/96                                                             Propensity score-matched study   ESD cases                    Depressed
  Nishizawa et al\[[@B43]\]   34/NA                                                             Case series                      Surveillance                 Depressed, intestinal type, relatively small
  Matsuo et al\[[@B44]\]      26/78                                                             Case control study               Surveillance                 Male, intestinal type, flat-depressed, low MUC2 and Wnt5a
  Yamamoto et al\[[@B45]\]    18/36                                                             Case control study               Early stage cancer           Smaller, lower Ki-67 index, depression, complete gastric type or gastric predominant mixed type
  Horiguchi et al\[[@B48]\]   71/115                                                            Case control study               Case series                  Non-tumorous epithelium Surface differentiation
  Ito et al\[[@B52]\]         29/NA                                                             Case series                      ESD cases                    Normal columnar epithelium
  Kitamura et al\[[@B53]\]    27/27                                                             Case control study               Endoscopic resection cases   Low-grade atypia on the surface
  Hori et al\[[@B54]\]        59/152                                                            Case control study               Endoscopic resection cases   Non-neoplastic epithelium, flattening of tumors, muting of the whitish discoloration

NA: Not applicable; ESD: Endoscopic submucosal dissection.

**Gastritis like appearance:** Another important characteristic of gastric cancer after *H. pylori* eradication is its gastritis-like appearance. This was initially reported by Kobayashi et al\[[@B46]\]. A "gastritis-like" appearance under narrow-band imaging with magnifying endoscopy was characterized by uniform papillae and/or tubular pits with a whitish border, regular or faint microvessels, and unclear demarcation, resembling the adjacent noncancerous mucosa (Figure [1](#F1){ref-type="fig"}). They examined retrospectively, differentiated-type early gastric cancer of 50 lesions after eradication, and 50 lesions without eradication. A "gastritis-like" appearance was more frequent for the eradication group (22/50) than the control group (2/50), and the "gastritis-like" appearance correlated with histological surface differentiation\[[@B46]\]. They also reported that the development of "gastritis-like" appearance was associated with less endoscopic atrophy\[[@B47]\]. These phenotypic characteristics or changes make the diagnosis of gastric cancer after *H. pylori* eradication difficult. In fact, it is reported that utilization of chromoendoscopy did not improve the diagnostic reliability of gastric cancer after *H. pylori* eradication\[[@B48]\]. These endoscopic characteristics of gastric cancer after eradication were associated with histological features that have been termed "non-neoplastic epithelium" (Discussed in the following chapter).

![Gastritis-like appearance. A: White light image by conventional endoscopy. Slightly reddish depressed lesion is detected in posterior wall of the upper part of the corpusl; B: A gastritis-like appearance under narrow-band imaging under magnifying endoscopy; C: Well-differentiated tubular adenocarcinoma with low-grade atypia (HE, orig. mag. ×100). Note the non-neoplastic epithelium (arrows) partially covered the surface of the adenocarcinoma (arrowheads).](WJG-24-2163-g001){#F1}

**Other:** Smaller tumor size is also reported as a characteristic of gastric cancer in *H. pylori-*eradicated cases. Yamamoto et al\[[@B45]\] reported that the average diameter of gastric cancer detected after successful eradication was smaller than that in non-eradicated, age, sex, and cancer-depth matched controls. However the control group did not undergo the routine follow-up examination that was performed in the eradicated group. Another propensity-matched study indicated similar tumor size in *H. pylori*-eradicated and infected patients\[[@B42]\].

Histology
---------

Other characteristics of gastric cancer detected after *H. pylori* eradication by histological assessment.

**Intestinal type:** We have previously conducted a cohort study of 573 *H. pylori-*eradicated cases. During the 6.2 ± 4.8 years of the observation period, we found 21 cases of primary gastric cancer in these *H. pylori-*eradicated patients\[[@B31]\]. Among the 21 tumors, 20 (95%) were intestinal-type gastric cancer, while only one was diffuse type. We did not compare those cancers with non-eradicated cases; however, before eradication therapy, the numbers of intestinal and diffuse-type gastric cancers were roughly even\[[@B49]\]. We speculate that *Helicobacter* eradication could lead to the dominance of intestinal-type gastric cancer. This intestinal-type dominance (*i.e*., diffuse-type reduction) was also reported in other studies\[[@B35],[@B50],[@B51]\]. However, several studies did not show differences in histological type between *H. pylori-*eradicated and non-eradicated cases\[[@B42],[@B45]\]. These studies analyzed only endoscopic treatment cases, which inevitably exclude diffuse-type cancers. This reduction of diffuse-type gastric cancer by *H. pylori* eradication will be clarified in future large-scale analysis.

**Non-neoplastic epithelium:** This histological characteristic was initially described in a study that evaluated the histological change of gastric tumors after *Helicobacter pylori* eradication\[[@B52]\]. They named non-neoplastic epithelium which often appeared on the surface of gastric cancer after eradication as epithelium with low-grade atypia (ELA). ELA was observed in 22 out of 27 gastric cancer cases detected after successful eradication where gastric-type mucin was frequently expressed\[[@B53]\]. Hori et al. compared 59 tumors detected after eradication and 152 detected while infected, and showed that the histological length ratio of non-neoplastic epithelium to the tumor was 8% for the eradicated group, and 0% for the infected group. The extension of non-neoplastic epithelium has been reported in several other studies (Table [1](#T1){ref-type="table"})\[[@B48],[@B54]\].

**Other:** One study evaluated Ki67 staining, which is a molecular indicator of cell proliferation. The Ki67 index was lower in the eradicated group than in the non-eradicated group. Immunohistochemical phenotyping revealed that gastric cancer after eradication was more often gastric-predominant type\[[@B45]\]. Another study investigated mucus patterns and Wnt5a expression in gastric cancer specimens derived from *H. pylori*-eradicated and infected patients. The result showed MUC2 and Wnt5a expressions were significantly lower in gastric cancers from *H. pylori*-eradicated patients\[[@B44]\].

PREDICTORS OF PRIMARY GASTRIC CANCER AFTER *H. PYLORI* ERADICATION
==================================================================

In this section, we summarize risk factors for gastric cancer development after *H. pylori* eradication. There are several cohort studies\[[@B31],[@B32],[@B55]-[@B58]\] and case-control studies\[[@B59]-[@B63]\] on this topic (Table [2](#T2){ref-type="table"}). These studies have examined patients' characteristics, endoscopic features, and histological findings associated with gastric cancer after *H. pylori* eradication.

###### 

Risk factor of gastric cancer development after *Helicobacter pylori* eradication

  **Ref**.                                         **Subject number**   **Study design**         **Diagnosis**                                    **Age**   **Follow-up period (yr)**   **Number of cancer**   **Risk factor**
  ------------------------------------------------ -------------------- ------------------------ ------------------------------------------------ --------- --------------------------- ---------------------- -----------------------------
  Shichijo et al\[[@B31]\]                         573                  Cohort study             CG/DU/GU                                         58        6.4                         21                     Endoscopic severe atrophy
  Histologic intestinal metaplasia                                                                                                                                                                             
  Take et al\[[@B32]\]                             1674                 Cohort study             GU/DU                                            51        5.6                         28                     Endoscopic severe atrophy
  Toyoshima et al\[[@B55]\]                        1232                 Cohort study             CG/DU/GU                                         54        2.5                         15                     Endoscopic severe atrophy
  Sakitani et al\[[@B56]\]                         965                  Cohort study             CG/DU/GU                                         63        4.5                         21                     Endoscopic severe atrophy
  Cheung et al\[[@B57]\]                           63397                Cohort study             *Helicobacter pylori* infection (GU 2%, DU 3%)   55        7.6                         153                    Proton pump inhibitor
  Takata et al\[[@B58]\]                           101                  Cohort study             CG/GU/GC                                         56        5.3                         8                      Age
  Kodama et al\[[@B59]\]                           2355                 Matched control study    CG/DU/GU/GC                                      63        4.1                         21                     Endoscopic severe atrophy
  OLGA staging                                                                                                                                                                                                 
  Histologic atrophy at the antrum                                                                                                                                                                             
  Histologic inflammation at the corpus                                                                                                                                                                        
  Histologic intestinal metaplasia at the corpus                                                                                                                                                               
  Sugimoto et al\[[@B60]\]                         1200                 Cross- sectional study   NA                                               70        4.6                         79                     Endoscopic severe atrophy
  Haneda et al\[[@B62]\]                           261                  Cross sectional study    CG/DU/GU/GC/MALToma/hyperplastic polyp           57        NA                          47                     Pepsinogen I/II ratio ≤ 4.5
  Maeda et al\[[@B63]\]                            177                  Cross sectional study    NA                                               NA        NA                          94                     Epigenetic marker

GU: Gastric ulcer; DU: Duodenal ulcer; CG: Chronic gastritis; GC: Gastric cancer; NA: Not available.

Endoscopic gastric atrophy
--------------------------

The classification of endoscopic atrophy was first described by Kimura and Takemoto in 1969 to discriminate the histological border between the pyloric and fundic glands\[[@B64]\]. They found a close association between this boundary and gastritis. Later, Uemura et al. showed, in their important report, which indicated the critical involvement of *H. pylori* in gastric carcinogenesis, that severe endoscopic atrophy was a risk factor for primary gastric cancer development in *H. pylori*-infected cases\[[@B10]\].

As for patients in whom *H. pylori* had been eradicated, Take et al. investigated risk factors associated with gastric cancer development in 1674 *H. pylori-*eradicated peptic ulcer patients\[[@B32]\]. In their mean 5.6-year surveillance endoscopy program following *H. pylori* eradication, they found 28 cases of gastric cancer in patients with a mean age of 51 years. Patients with severe endoscopic gastric atrophy, which they defined as Kimura-Takemoto classification O2 and O3, before eradication had increased risk for gastric cancer (0.62% per year), compared to patients with mild (C1 and C2) and moderate (C3 and O1) atrophy (0.04% and 0.28% per year, respectively).

We also examined endoscopic atrophy for the prediction of gastric cancer in the above-mentioned study\[[@B31]\]. Multivariate analysis revealed that histologic intestinal metaplasia and severe endoscopic atrophy are independent risks for gastric cancer development. In our study, patients with O2 or O3 atrophy at eradication had 9.3-fold risk for developing gastric cancer compared to patients with no or mild atrophy (C0-C2) in multivariate analysis. Many other cohort studies\[[@B55],[@B56]\] and case-control studies\[[@B59],[@B60]\] showed similar results, that severe endoscopic atrophy is associated with gastric cancer development in *H. pylori-*eradicated patients (Table [2](#T2){ref-type="table"}).

Histological intestinal metaplasia
----------------------------------

Another well-characterized gastric cancer risk is histological intestinal metaplasia, evaluated at the time of eradication therapy (Figure [2](#F2){ref-type="fig"}). It has been suggested that intestinal metaplasia precedes gastric cancer development, especially for intestinal-type cancer\[[@B11],[@B13]\]. There have been debates on whether this histological change is a precancerous or a paracancerous lesion, which has not yet been completely clarified. Nonetheless, several observational studies have indicated that the presence of intestinal metaplasia in the background gastric tissue indicates a higher risk for accompanying or developing gastric cancer\[[@B10],[@B17],[@B18],[@B65],[@B66]\].

![Intestinal metaplasia in the corpus. A: Endoscopic image of the intestinal metaplasia in the corpus. Greyish-white, slightly opalescent, flat, elevated lesions of various sizes; B: Narrow-band imaging under a magnifying endoscopy image, light blue crest appears as blue-white lines visible on the epithelial surface\[[@B75]\]; C: Microscopic picture of a biopsy specimen with intestinal metaplasia (HE, orig. mag. ×100).](WJG-24-2163-g002){#F2}

As described above, we have analyzed 573 endoscopy-based surveillance cases after *H. pylori* eradiation, in which 21 cases of gastric cancer were observed\[[@B31]\]. Before eradication, participants had been evaluated for the presence of intestinal metaplasia\[[@B17],[@B18]\] and neutrophil infiltration using antral and corpus biopsies, and the degree of endoscopic atrophy. We classified patients into three groups according to the histological metaplasia distribution\[[@B17],[@B18]\]. Compared to the group with no intestinal metaplasia, patients with metaplasia limited to antrum had a 4.5-fold increased risk, and patients with metaplasia in corpus had a 7.6-fold increased risk in univariate analysis. Multivariate analysis revealed that the presence of histologic intestinal metaplasia was an independent risk for gastric cancer development. To the best of our knowledge this is the first report that shows intestinal metaplasia as the predictor of future gastric cancer after *H. pylori* eradication.

Kodama et al\[[@B59]\] performed cross-sectional and case-control analyses of an *H. pylori-*eradicated cohort and reported that the histological intestinal metaplasia score in the corpus was significantly higher in gastric cancer cases than that in age- and sex- matched non-cancer controls. This study also evaluated the intestinal metaplasia score in the antrum, which did not show a statistical difference between the two groups. Taken together, the presence of intestinal metaplasia, especially in the corpus, might indicate a higher risk for developing gastric cancer.

Long-term use of proton pump inhibitors
---------------------------------------

Cheung et al\[[@B57]\] recently reported, based on a territory-wide health database of Hong Kong, that long term use of proton pump inhibitors (PPI) was associated with an increased gastric cancer risk in subjects after *H. pylori-*eradication therapy. Among 63397 eligible patients who received clarithromycin-based triple therapy between 2003 and 2012, 153 cases of gastric cancer developed before 2015. The risk increased with duration of PPI use (Hazard ratio 5.0, 6.7, and 8.3 for ≥ 1, 2, and 3 years, respectively). Many researchers quickly responded to this topic, and both affirming\[[@B67]\] and contradicting reports\[[@B68],[@B69]\] followed this paper. Interestingly, another population-based study in Sweden also indicated the increased risk of gastric cancer (regardless of *H. pylori* infection or eradication) in maintenance therapy with PPI\[[@B70]\]. Contrary to the former study on *H. pylori-*eradicated cases\[[@B57]\], this study did not find that the risk increased with therapeutic duration. Therefore, this topic still requires more study before a consensus can be reached, but clinicians should take PPI use into account for future studies of gastric cancer risk assessment.

Other
-----

Age factor has also been reported in many studies. Most studies showed an older age at eradication is associated with an increased risk of developing cancer in univariate analysis\[[@B31],[@B55],[@B59]\]. However, age is also closely associated with other gastritis-related phenotypes, which often lead to less value in carcinogenesis under multivariate analysis. For example, a cohort study examined 101 histologically diagnosed corpus atrophic gastritis patients who underwent successful eradication therapy\[[@B58]\]. This study found eight gastric cancer cases (all intestinal type) during a mean follow-up period of 5.3 year, and the patients' characteristics and serum biochemistry data were compared in the groups with and without cancer. Out of age, sex, the disease indicated for eradication (gastritis or gastric ulcer), prior gastric cancer, pepsinogen value, and gastrin value, only age (64 years *vs* 55 years) was statistically different between groups. However, lack of multivariate analysis or other important confounding factors, such as endoscopic atrophy or histological metaplasia, might have led to an immature conclusion in this study.

Endoscopic diagnosis associated with *H. pylori* infection has been examined as a risk or protective factor for gastric cancer development. In a *H. pylori-*persistent infection cohort, reduced risk for gastric cancer development was found specifically in duodenal ulcer patients (0 out of 275 for duodenal ulcer *vs* 36 out of 971 for other diseases)\[[@B10]\]. As for patients after eradication therapy, Kamada et al\[[@B41]\] reported that no gastric cancer developed in 654 duodenal ulcer patients, while 12 of 575 (2.1%), two of 453 (0.4%), and six of 105 (5.7%) cases were reported in gastric ulcer, atrophic gastritis and endoscopic resection for early gastric cancer patients, respectively. Kodama et al\[[@B59]\]. also reported only three gastric cancer cases, developed from 655 patients with duodenal ulcers (0.5%), while 10 of 902 (1.1%), 14 of 593 (2.4%), and 3 of 51 (5.9%) cases developed from patients with chronic gastritis, gastric ulcers, and gastric cancer, respectively. These reports indicate duodenal ulcer patients who received eradication therapy have less risk for future gastric cancer occurrence than do patients who have undergone eradication for other *H. pylori*-related diseases.

Pepsinogen (PG) methods are clinically used for the gastric-cancer screening program in Japan. As low PGI levels and low PGI/II ratios are correlated with mucosal atrophy, the efficacy of this screening method for identifying high-risk subjects of gastric cancer has been reported in multiple cohort studies\[[@B71],[@B72]\]. However PG values and ratios change after *H. pylori* eradication\[[@B73]\], and the usefulness of the PG method in *H. pylori-*eradicated patients was not evident. Haneda et al\[[@B62]\]. examined PG levels in post-eradication cases with and without gastric cancer, and found that the optimal cut-off value for the PGI/II ratio was 4.5 (instead of the usual 3.0). The usefulness of this cut-off value in clinical practice needs to be confirmed in a cohort or a prospective study.

Finally, molecular indicators of gastric cancer risk have been investigated intensively. Recent research, focused on epigenetic markers, has revealed completely new types of gastric cancer risk predictors. In a case-control study consisting of eight cases without infection, 75 atrophic gastritis post-eradication cases and 94 gastric cancer post-eradication cases, nine candidate epigenetic markers, which showed elevated methylation levels in cancer cases, were isolated\[[@B63]\]. These new markers are now being evaluated in a prospective cohort study, which will elucidate the clinical usefulness of these molecular approaches in the near future.

PERSPECTIVES
============

Here we have reviewed characteristics and predictors of gastric cancer after *H. pylori* eradication. Knowledge of endoscopic characteristics, such as depressed and gastritis-like appearance, and an understanding of the histological non-neoplastic epithelium, will be helpful in detecting gastric cancer while screening subjects after eradication therapy. Reportedly, the tumors detected after *H. pylori* eradication seemed to be less proliferative and more gastric phenotype. This might be associated with a differentiation program by adult-tissue stem cells, and the mechanism of these molecular changes and the effect of *H. pylori* eradication will be an interesting research project. As for predictors, severe endoscopic atrophy, histologic intestinal metaplasia before eradication, and PPI use are reportedly risk factors for gastric cancer development after eradication. Cases with these risk factors should be carefully followed up by endoscopy, with special attention paid to the aforementioned characteristic endoscopic findings.

So far, most of the risk factors were evaluated before the eradication, which is helpful for identifying high-risk patients early so they can be invited into a surveillance program. However, risk stratification according to findings after eradication, not those before eradication, might be more practical, because information prior to eradication is not always available. For example, we proposed that histological intestinal metaplasia is an important risk factor for future gastric cancer development, but most of the *H. pylori-*eradicated subjects in the community did not receive a histological evaluation prior to eradication. If there is little change in the metaplasia after eradication, then assessment of histology after eradication may be used as a substitute, but this would need to be evaluated by independent studies. Risk stratification by pepsinogen levels after eradication has been reported\[[@B62]\], but further validation studies are necessary. Some researchers have focused on endoscopic changes after *H. pylori* eradication that was accompanied with cancer\[[@B74]\]. Map-like redness after eradication, which corresponds to intestinal metaplasia histologically, could be a predictor for metachronous gastric cancer. Importantly, recent retrospective epigenetic research used gastric samples collected from post-eradication cases, which is ideally applicable to all subjects\[[@B63]\]. Therefore the result of the ongoing prospective study is highly anticipated.

Eradication therapy is relatively new, and current studies are mostly limited to elder patients over 50 years old. Therefore, further long-term follow-up studies, over several decades, or a study of the young population should be required to form a consensus for an adequate surveillance program. Based on the results reviewed in this paper, it is safe to propose annual endoscopic surveillance for high-risk *H. pylori*-eradicated patients, such as those with severe endoscopic atrophic gastritis (O2 or O3) or histological intestinal metaplasia before eradication. Patients who require PPI treatment for any reason after eradication should also have an annual checkup for both gastric cancer surveillance and for the conditions requiring PPI. However, for other relatively low-risk eradicated patients, such as subjects with mild atrophy or no metaplasia, little evidence exists to propose a proper surveillance program. As these relatively low risk patients consist of the majority of *H. pylori-*eradicated cases, studies targeting these subjects will definitely be required. New studies, new modalities, and new concepts will lead to the establishment of a primary gastric cancer surveillance program suitable for all *H. pylori-*eradicated cases according to their cancer risk stratification.

CONCLUSION
==========

In this review article, we have summarized the previous studies on the characteristics and predictors of gastric cancer which developed after successful *H. pylori* eradication. Gastric cancer surveillance program after *H. pylori* eradication according to risk stratification needs to be established in future.
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